CN107249616A - 芋螺毒素(conotoxin)肽的修饰和用途 - Google Patents

芋螺毒素(conotoxin)肽的修饰和用途 Download PDF

Info

Publication number
CN107249616A
CN107249616A CN201580068468.7A CN201580068468A CN107249616A CN 107249616 A CN107249616 A CN 107249616A CN 201580068468 A CN201580068468 A CN 201580068468A CN 107249616 A CN107249616 A CN 107249616A
Authority
CN
China
Prior art keywords
arg
xaa
cys
res
mod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580068468.7A
Other languages
English (en)
Chinese (zh)
Inventor
S·P·艾度纳托
E·J·穆诺茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qinita Chronic Pain LLC
Original Assignee
Qinita Chronic Pain LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qinita Chronic Pain LLC filed Critical Qinita Chronic Pain LLC
Publication of CN107249616A publication Critical patent/CN107249616A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Insects & Arthropods (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201580068468.7A 2014-11-07 2015-11-06 芋螺毒素(conotoxin)肽的修饰和用途 Pending CN107249616A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462123123P 2014-11-07 2014-11-07
US62/123,123 2014-11-07
PCT/US2015/059613 WO2016073949A1 (en) 2014-11-07 2015-11-06 Modifications and uses of conotoxin peptides

Publications (1)

Publication Number Publication Date
CN107249616A true CN107249616A (zh) 2017-10-13

Family

ID=55909927

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580068468.7A Pending CN107249616A (zh) 2014-11-07 2015-11-06 芋螺毒素(conotoxin)肽的修饰和用途

Country Status (12)

Country Link
US (2) US11014970B2 (de)
EP (1) EP3215172B1 (de)
JP (3) JP6798998B2 (de)
KR (1) KR102623475B1 (de)
CN (1) CN107249616A (de)
AU (2) AU2015342767B2 (de)
CA (1) CA2966865C (de)
ES (1) ES2950901T3 (de)
HK (1) HK1244201A1 (de)
IL (2) IL284236B2 (de)
TW (2) TWI708790B (de)
WO (1) WO2016073949A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115286700A (zh) * 2022-08-22 2022-11-04 中国海洋大学 一种具有血浆稳定性的镇痛多肽

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6798998B2 (ja) 2014-11-07 2020-12-09 キネタ・クロニック・ペイン・リミテッド・ライアビリティ・カンパニーＫｉｎｅｔａ Ｃｈｒｏｎｉｃ Ｐａｉｎ， ＬＬＣ コノトキシンペプチドの修飾および使用
RU2731217C2 (ru) * 2016-11-28 2020-08-31 Общество с ограниченной ответственностью "Синейро" Аналог альфа-конотоксина RgIA для лечения боли
US10947274B1 (en) * 2018-05-01 2021-03-16 University Of Utah Research Foundation Synthetic analgesic peptides of RgIA analogs
KR102117106B1 (ko) 2018-09-14 2020-06-01 대한민국(환경부 국립생물자원관장) N형 칼슘채널 차단 활성을 갖는 긴호랑거미 유래 알지신-ⅰ 펩타이드 및 이의 용도
CR20210363A (es) 2019-01-04 2021-12-10 Kineta Chronic Pain Llc Análogos de péptidos de canotoxina y usos para el tratamiento del dolor y de las afecciones inflamatorias
US11612661B2 (en) 2019-01-04 2023-03-28 Kineta Chronic Pain, Llc Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions
KR20230031884A (ko) * 2020-06-03 2023-03-07 유타대학연구재단 형태적으로 제약된 α-RGIA 유사체

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1379786A (zh) * 1999-10-18 2002-11-13 阿克佐诺贝尔公司 用于免疫治疗的修饰肽和肽类似物
CN101312986A (zh) * 2005-09-28 2008-11-26 日内瓦大学 生产修饰（多）肽的方法
CN101448516A (zh) * 2006-04-13 2009-06-03 昆士兰大学 环化α-芋螺毒素肽
US20120190827A1 (en) * 2006-09-08 2012-07-26 Ambrx, Inc. Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses
US20120220539A1 (en) * 2006-07-18 2012-08-30 University Of Utah Research Foundation Conotoxin peptides
WO2014194284A1 (en) * 2013-05-31 2014-12-04 Mcintosh J Michael Conotoxin peptides, pharmaceutical compositions and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595972A (en) 1993-06-29 1997-01-21 University Of Utah Research Foundation Conotoxin peptides
US6797808B1 (en) 1999-01-29 2004-09-28 University Of Utah Research Foundation α-conotoxin peptides
AU2003302610B2 (en) 2002-12-02 2008-03-20 Xenome Ltd Novel chi-conotoxin peptides (-II)
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US7745573B2 (en) * 2006-02-17 2010-06-29 Polychip Pharmaceuticals Pty Ltd. Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides
EP1834962A1 (de) * 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
EP2310407A4 (de) 2008-04-08 2011-09-14 Aileron Therapeutics Inc Biologisch wirksame peptidomimetische makrozyklen
DE102009050885A1 (de) * 2009-10-27 2011-04-28 Behr Gmbh & Co. Kg Luftausströmer
JP6798998B2 (ja) 2014-11-07 2020-12-09 キネタ・クロニック・ペイン・リミテッド・ライアビリティ・カンパニーＫｉｎｅｔａ Ｃｈｒｏｎｉｃ Ｐａｉｎ， ＬＬＣ コノトキシンペプチドの修飾および使用
US11612661B2 (en) 2019-01-04 2023-03-28 Kineta Chronic Pain, Llc Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1379786A (zh) * 1999-10-18 2002-11-13 阿克佐诺贝尔公司 用于免疫治疗的修饰肽和肽类似物
CN101312986A (zh) * 2005-09-28 2008-11-26 日内瓦大学 生产修饰（多）肽的方法
CN101448516A (zh) * 2006-04-13 2009-06-03 昆士兰大学 环化α-芋螺毒素肽
US20120220539A1 (en) * 2006-07-18 2012-08-30 University Of Utah Research Foundation Conotoxin peptides
US20120190827A1 (en) * 2006-09-08 2012-07-26 Ambrx, Inc. Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses
WO2014194284A1 (en) * 2013-05-31 2014-12-04 Mcintosh J Michael Conotoxin peptides, pharmaceutical compositions and uses thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BRIAN P. WARD等: "Peptide lipidation stabilizes structure to enhance biological function", 《MOLECULAR METABOLISM》 *
J. MILTON HARRIS等: "Effect of Pegylation on Pharmaceuticals", 《NATURE REVIEWS DRUG DISCOVERY》 *
KAI HOLLAND‐NELL等: "Maintaining Biological Activity by Using Triazoles as Disufide Bond Mimetics", 《ANGEW. CHEM. INT. ED》 *
RENATA KOWALCZYK等: "Synthesis and evaluation of disulfide bond mimetics of amylin-（1-8） as agents to treat osteoporosis", 《BIOORGANIC & MEDICINAL CHEMISTRY》 *
S.N. KOMPELLA等: "Dicarba modification of a-conotoxin RgIA conferring selectivity towards a9a10 nicotinic acetylcholine receptors", 《BIOCHEMICAL PHARMACOLOGY》 *
徐鸣夏: "《药物化学》", 31 May 1996, 中国医药科技出版社 *
薛大权等: "《聚乙二醇在医药学领域的应用与技术》", 30 April 2011, 华中科技大学出版社 *
金向群等: "《药学专业知识（二）》", 31 March 2009, 军事医学科学出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115286700A (zh) * 2022-08-22 2022-11-04 中国海洋大学 一种具有血浆稳定性的镇痛多肽

Also Published As

Publication number Publication date
EP3215172B1 (de) 2023-04-26
IL252152B (en) 2021-07-29
EP3215172A1 (de) 2017-09-13
AU2021212006A1 (en) 2021-08-26
ES2950901T3 (es) 2023-10-16
TWI777260B (zh) 2022-09-11
IL252152A0 (en) 2017-07-31
AU2021212006B2 (en) 2023-08-31
TW202120525A (zh) 2021-06-01
JP6798998B2 (ja) 2020-12-09
US20210122792A1 (en) 2021-04-29
JP2018500385A (ja) 2018-01-11
AU2015342767A1 (en) 2017-06-15
IL284236B2 (en) 2023-04-01
IL284236B (en) 2022-12-01
HK1244201A1 (zh) 2018-08-03
WO2016073949A1 (en) 2016-05-12
CA2966865C (en) 2023-03-21
US11014970B2 (en) 2021-05-25
CA2966865A1 (en) 2016-05-12
KR20170083574A (ko) 2017-07-18
TW201629085A (zh) 2016-08-16
IL284236A (en) 2021-08-31
AU2015342767B2 (en) 2021-05-13
TWI708790B (zh) 2020-11-01
US11618772B2 (en) 2023-04-04
US20180362599A1 (en) 2018-12-20
KR102623475B1 (ko) 2024-01-09
EP3215172A4 (de) 2018-07-25
JP2022063872A (ja) 2022-04-22
JP2020090550A (ja) 2020-06-11

Similar Documents

Publication Publication Date Title
CN107249616A (zh) 芋螺毒素(conotoxin)肽的修饰和用途
CN105308063B (zh) Wt1抗原肽缀合物疫苗
CN101111515B (zh) 胰多肽家族基序、包含该基序的多肽和方法
ES2529196T3 (es) Secuencias de nucleótidos y proteínas de genes Nogo y métodos basados en estas
CN102245626A (zh) 微型铁调素肽及其使用方法
BR112013029206B1 (pt) composto, e, uso de um composto
TWI686205B (zh) 芋螺毒素（ｃｏｎｏｔｏｘｉｎ）肽，其醫藥組合物及用途
CN108883166A (zh) 以成为疾病主要原因的生物体内蛋白质为靶标的结合疫苗
CN103648517A (zh) 神经保护肽
CN110248953A (zh) 新型订书肽及其用途
CN105985410A (zh) 新芋螺肽、其药物组合物及用途
CN110506054A (zh) 经工程改造的多肽
WO2002064740A9 (en) Cone snail peptides
ES2670999T3 (es) Un método de tratamiento del trastorno obsesivo compulsivo (TOC) o la ansiedad usando un anticuerpo que se une a la anexina-1
CN107849109A (zh) Il‑37变体
CN102088992A (zh) 肽基二酰基甘油酯
US7408028B2 (en) Peptides, antibodies thereto, and their use in treatment of central nervous system, damage
US10947274B1 (en) Synthetic analgesic peptides of RgIA analogs
CN1849132A (zh) 调节神经元生长的化合物以及它们的用途
CN103626866B (zh) 胰多肽家族基序、包含该基序的多肽和方法
WO2015169225A1 (zh) 四分支多肽化合物及其制备方法与应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Jeffrey Gerald Posaconi

Inventor before: S - P - Aldo Rothschild

Inventor before: E - J - Munuoci